JP2019500374A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500374A5 JP2019500374A5 JP2018533649A JP2018533649A JP2019500374A5 JP 2019500374 A5 JP2019500374 A5 JP 2019500374A5 JP 2018533649 A JP2018533649 A JP 2018533649A JP 2018533649 A JP2018533649 A JP 2018533649A JP 2019500374 A5 JP2019500374 A5 JP 2019500374A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- alkyl
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 16
- 239000012453 solvate Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000000651 prodrug Substances 0.000 claims 15
- 229940002612 prodrug Drugs 0.000 claims 15
- 125000004452 carbocyclyl group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 3
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021103372A JP2021167323A (ja) | 2015-12-23 | 2021-06-22 | グルココルチコイド受容体の阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387282P | 2015-12-23 | 2015-12-23 | |
| US62/387,282 | 2015-12-23 | ||
| PCT/US2016/068431 WO2017112902A1 (en) | 2015-12-23 | 2016-12-22 | Inhibitors of glucocorticoid receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103372A Division JP2021167323A (ja) | 2015-12-23 | 2021-06-22 | グルココルチコイド受容体の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500374A JP2019500374A (ja) | 2019-01-10 |
| JP2019500374A5 true JP2019500374A5 (enExample) | 2020-01-30 |
| JP6906525B2 JP6906525B2 (ja) | 2021-07-21 |
Family
ID=59091239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018533649A Expired - Fee Related JP6906525B2 (ja) | 2015-12-23 | 2016-12-22 | グルココルチコイド受容体の阻害剤 |
| JP2021103372A Ceased JP2021167323A (ja) | 2015-12-23 | 2021-06-22 | グルココルチコイド受容体の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103372A Ceased JP2021167323A (ja) | 2015-12-23 | 2021-06-22 | グルココルチコイド受容体の阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11124537B2 (enExample) |
| EP (1) | EP3394078A4 (enExample) |
| JP (2) | JP6906525B2 (enExample) |
| CN (1) | CN108699102A (enExample) |
| AU (2) | AU2016377702B2 (enExample) |
| CA (1) | CA3009522A1 (enExample) |
| WO (1) | WO2017112902A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11124537B2 (en) | 2015-12-23 | 2021-09-21 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| WO2017112909A1 (en) | 2015-12-23 | 2017-06-29 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| WO2017112904A1 (en) | 2015-12-23 | 2017-06-29 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| KR20210039001A (ko) | 2016-10-07 | 2021-04-08 | 오릭 파마슈티칼스, 인크. | 글루코코르티코이드 수용체의 억제제 |
| US11998606B2 (en) | 2018-04-13 | 2024-06-04 | Board Of Regents, The University Of Texas System | Compounds and methods for selective proteolysis of glucocorticoid receptors |
| US20230302014A1 (en) * | 2020-08-04 | 2023-09-28 | Oric Pharmaceuticals, Inc. | Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations |
| KR20230061485A (ko) * | 2020-08-31 | 2023-05-08 | 더 트러스티즈 오브 인디애나 유니버시티 | 항프로게스틴을 투여하여 고등급 장액성 난소암 및 유방암을 예방하는 방법 |
| WO2023000135A1 (en) * | 2021-07-19 | 2023-01-26 | Context Biopharma Inc. | Processes of making onapristone and intermediates thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA8231B (en) * | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
| FR2528434B1 (fr) | 1982-06-11 | 1985-07-19 | Roussel Uclaf | Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament |
| FR2522328B1 (fr) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
| JP2785023B2 (ja) * | 1987-12-30 | 1998-08-13 | ルセル―ユクラフ | １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物 |
| JPH02188599A (ja) | 1988-11-16 | 1990-07-24 | Roussel Uclaf | ３―ケト―デルタ―４，９―１９―ノルステロイドから誘導される新物質及びそれらよりなる薬剤 |
| DE3921059A1 (de) | 1989-06-23 | 1991-01-10 | Schering Ag | 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel |
| FR2651435A1 (fr) | 1989-09-07 | 1991-03-08 | Roussel Uclaf | Nouvelle utilisation de composes anti-progestomimetiques. |
| DE4018167A1 (de) | 1990-06-01 | 1991-12-05 | Schering Ag | Verfahren zur herstellung von 10(beta)-h-steroiden |
| DE4042007A1 (de) | 1990-12-22 | 1992-06-25 | Schering Ag | 6,7-modifizierte-11(beta)-aryl-4-estrene |
| JP3828926B2 (ja) | 1993-08-04 | 2006-10-04 | アクゾ・ノベル・エヌ・ベー | 不安症の治療用抗グルココルチコイドステロイド |
| AU1439595A (en) | 1993-12-22 | 1995-07-10 | Salk Institute For Biological Studies, The | Methods for reducing multidrug resistance |
| ES2196063T3 (es) | 1995-02-02 | 2003-12-16 | Schering Ag | Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales. |
| IL118974A (en) * | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
| IL122740A (en) * | 1997-01-15 | 2003-09-17 | Akzo Nobel Nv | 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them |
| CN1085078C (zh) | 1998-01-07 | 2002-05-22 | 沈志华 | 用于大月份引产的复合药物 |
| US6512130B1 (en) | 2000-09-05 | 2003-01-28 | Council Of Scientific And Industrial Research | Mifepristone analogue, process for the preparation thereof and use thereof |
| EP1285927A3 (de) | 2001-08-16 | 2005-06-29 | Schering Aktiengesellschaft | Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems |
| US7250408B2 (en) | 2002-12-16 | 2007-07-31 | Bayer Schering Pharma Ag | Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility |
| US7671045B2 (en) * | 2006-02-17 | 2010-03-02 | Janssen Pharmaceutica N.V. | 17-phosphorous steroid derivatives useful as progesterone receptor modulators |
| EP3020706A1 (en) | 2006-03-29 | 2016-05-18 | The Regents Of The University Of California | Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder |
| HUE029397T2 (en) | 2007-04-20 | 2017-03-28 | Preglem Sa | Selective progesterone modulators for treating uterine bleeding |
| WO2012106514A2 (en) | 2011-02-03 | 2012-08-09 | Pop Test Cortisol Llc | System and method for diagnosis and treatment |
| EP2545922A1 (en) | 2011-07-12 | 2013-01-16 | PregLem S.A. | Treatment of excessive menstrual bleeding associated with uterine fibroids |
| US20130029953A1 (en) * | 2011-07-28 | 2013-01-31 | Klaus Nickisch | Progesterone antagonists |
| DK3111950T3 (da) | 2012-02-24 | 2021-10-04 | Univ Chicago | Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer |
| EP2641602A1 (en) | 2012-03-23 | 2013-09-25 | PregLem S.A. | Method for treating gynecological diseases |
| US9096641B2 (en) | 2013-06-05 | 2015-08-04 | Evestra, Inc. | Imidazolyl progesterone antagonists |
| WO2015089338A2 (en) | 2013-12-11 | 2015-06-18 | Sloan-Kettering Institute For Cancer Research | Glucocorticoid inhibitors for treatment of prostate cancer |
| CN104530166B (zh) | 2014-12-04 | 2016-08-24 | 陕西汉江药业集团股份有限公司 | 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法 |
| WO2017112909A1 (en) | 2015-12-23 | 2017-06-29 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| WO2017112904A1 (en) | 2015-12-23 | 2017-06-29 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| US11124537B2 (en) * | 2015-12-23 | 2021-09-21 | Oric Pharmaceuticals, Inc. | Inhibitors of glucocorticoid receptor |
| KR20210039001A (ko) | 2016-10-07 | 2021-04-08 | 오릭 파마슈티칼스, 인크. | 글루코코르티코이드 수용체의 억제제 |
| US12233073B2 (en) | 2017-06-09 | 2025-02-25 | Regents Of The University Of Minnesota | Skin care formulations and skin cancer treatment |
| JP2021518842A (ja) | 2018-04-11 | 2021-08-05 | オリック ファーマシューティカルズ，インク． | グルココルチコイド受容体アンタゴニストを含む固体の形態と製剤、およびその使用 |
-
2016
- 2016-12-22 US US16/065,626 patent/US11124537B2/en not_active Expired - Fee Related
- 2016-12-22 AU AU2016377702A patent/AU2016377702B2/en not_active Ceased
- 2016-12-22 WO PCT/US2016/068431 patent/WO2017112902A1/en not_active Ceased
- 2016-12-22 JP JP2018533649A patent/JP6906525B2/ja not_active Expired - Fee Related
- 2016-12-22 EP EP16880121.5A patent/EP3394078A4/en not_active Withdrawn
- 2016-12-22 CA CA3009522A patent/CA3009522A1/en active Pending
- 2016-12-22 CN CN201680082458.3A patent/CN108699102A/zh active Pending
-
2021
- 2021-03-31 AU AU2021202019A patent/AU2021202019B2/en not_active Ceased
- 2021-06-22 JP JP2021103372A patent/JP2021167323A/ja not_active Ceased
- 2021-08-17 US US17/404,493 patent/US20210395295A1/en not_active Abandoned